Hendrych Michal, Solar Peter, Hermanova Marketa, Slaby Ondrej, Valekova Hana, Vecera Marek, Kopkova Alena, Mackerle Zdenek, Kazda Tomas, Pospisil Petr, Lakomy Radek, Chrastina Jan, Sana Jiri, Jancalek Radim
First Department of Pathology, St. Anne's University Hospital Brno and Faculty of Medicine, Masaryk University, 602 00 Brno, Czech Republic.
Department of Neurosurgery, St. Anne's University Hospital Brno and Faculty of Medicine, Masaryk University, 602 00 Brno, Czech Republic.
Diagnostics (Basel). 2023 Jan 4;13(2):181. doi: 10.3390/diagnostics13020181.
Glioblastoma (GBM) is regarded as an aggressive brain tumor that rarely develops extracranial metastases. Despite well-investigated molecular alterations in GBM, there is a limited understanding of these associated with the metastatic potential. We herein present a case report of a 43-year-old woman with frontal GBM with primitive neuronal component who underwent gross total resection followed by chemoradiation. Five months after surgery, the patient was diagnosed with an intraspinal GBM metastasis. Next-generation sequencing analysis of both the primary and metastatic GBM tissues was performed using the Illumina TruSight Tumor 170 assay. The number of single nucleotide variants observed in the metastatic sample was more than two times higher. Mutations in , , and found in the primary and metastatic tissue samples indicated the mesenchymal molecular GBM subtype. Among others, there were two inactivating mutations (Arg1026Ile, Trp1831Ter) detected in the gene, two novel variants of unknown significance predicted to be damaging (Pro1505Thr, Cys1099Tyr), one novel variant of unknown significance (Arg1046Ser), and one gene fusion of unknown significance, , in the metastatic sample. Based on the literature evidence, the alterations of , , and could explain, at least in part, the acquired invasiveness and metastatic potential in this particular GBM case.
胶质母细胞瘤(GBM)被认为是一种侵袭性脑肿瘤,很少发生颅外转移。尽管对GBM的分子改变进行了充分研究,但对与转移潜能相关的改变了解有限。我们在此报告一例43岁患有额叶GBM伴原始神经成分的女性病例,该患者接受了肿瘤全切除,随后进行了放化疗。术后五个月,患者被诊断为脊髓内GBM转移。使用Illumina TruSight Tumor 170检测法对原发性和转移性GBM组织进行了二代测序分析。在转移样本中观察到的单核苷酸变异数量高出两倍多。在原发性和转移性组织样本中发现的、和的突变表明为间充质分子GBM亚型。其中,在转移样本中检测到基因有两个失活突变(Arg1026Ile、Trp1831Ter),两个预测为有害的意义不明的新变异(Pro1505Thr、Cys1099Tyr),一个意义不明的新变异(Arg1046Ser),以及一个意义不明的基因融合,。基于文献证据,、和的改变至少可以部分解释该特定GBM病例中获得性侵袭性和转移潜能。